跳至主要内容
临床试验/NCT03420066
NCT03420066已完成不适用

NEXUS™ Aortic Arch Stent Graft System Data Collection Study for Compassionate-Use Procedures

Endospan Ltd.4 个研究点 分布在 3 个国家目标入组 7 人开始时间: 2018年2月19日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
Endospan Ltd.
入组人数
7
试验地点
4
主要终点
Performance Evaluation Criteria

研究概览

简要总结

A Multicenter, observational Data Collection Study to Evaluate the Safety and Performance of the Nexus™ Aortic Arch Stent Graft System in patients that were implanted with the device as part of Compassionate Use Procedures.

详细描述

The purpose of the study is to collect and analyze data that is recorded as standard of care for patients that were implanted with the Nexus device as part of Compassionate Use Procedures.The data will be used to obtain additional information on the safety and performance of the Nexus™ Aortic Arch Stent Graft System in patients affected by pathologies involving the aortic arch.

Data will be collected at each time point of patient's follow up conducted according to the standard of care in each site.

研究设计

研究类型
Observational
观察模型
Case Only
时间视角
Retrospective

入排标准

性别
All
接受健康志愿者

入选标准

  • Patients for whom the Nexus implantation was initiated as part of a compassionate use procedure.
  • A signed and dated Informed Consent document is available that authorizes to collect the patient's personal data following implantation of the Nexus systems and throughout the follow ups visits up to 5 years following implantation.

排除标准

  • There are no exclusions. Data will be collected for all implanted population as described in the inclusion section above

结局指标

主要结局

Performance Evaluation Criteria

时间窗: within 30 days post implantation

Successful disease treatment at 30 days post implantation, defined as Stent Graft positioned in the aortic arch isolating the diseased lesion based on review of medical charts by the Investigators.

Primary Safety Evaluation Criteria

时间窗: within 30 days post implantation

Device related mortality at 30 days post implantation based on review of medical charts by the Investigators

次要结局

  • Secondary Safety Evaluation Criteria(within 1 year post-implantation)

研究者

发起方
Endospan Ltd.
申办方类型
Industry
责任方
Sponsor

研究点 (4)

Loading locations...

相似试验

The NEXUS™ Compassionate Use Data Collection Study | 临床试验